A spectrum of changes occurs in peptidoglycan composition of glycopeptide-intermediate clinical Staphylococcus aureus isolates
about
Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implicationsCellular impermeability and uptake of biocides and antibiotics in Gram-positive bacteria and mycobacteriaIdentification and in vitro analysis of the GatD/MurT enzyme-complex catalyzing lipid II amidation in Staphylococcus aureusCoagulase-negative staphylococci.A mutation in the PP2C phosphatase gene in a Staphylococcus aureus USA300 clinical isolate with reduced susceptibility to vancomycin and daptomycin.DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus.Exploring glycopeptide-resistance in Staphylococcus aureus: a combined proteomics and transcriptomics approach for the identification of resistance-related markers.Toluidine blue-mediated photodynamic effects on staphylococcal biofilmsPhotodynamic effects of novel XF porphyrin derivatives on prokaryotic and eukaryotic cells.Nationwide survey shows that methicillin-resistant Staphylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals.tcaA inactivation increases glycopeptide resistance in Staphylococcus aureus.An elevated mutation frequency favors development of vancomycin resistance in Staphylococcus aureus.Vancomycin susceptibility of oxacillin-resistant Staphylococcus aureus isolates causing nosocomial bloodstream infections.Structural variations of the cell wall precursor lipid II and their influence on binding and activity of the lipoglycopeptide antibiotic oritavancin.The msaABCR operon regulates resistance in vancomycin-intermediate Staphylococcus aureus strains.Fast and effective photodynamic inactivation of multiresistant bacteria by cationic riboflavin derivativesIn vivo survival of teicoplanin-resistant Staphylococcus aureus and fitness cost of teicoplanin resistance.Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureusMorphological and genetic differences in two isogenic Staphylococcus aureus strains with decreased susceptibilities to vancomycin.Transcriptomic and functional analysis of an autolysis-deficient, teicoplanin-resistant derivative of methicillin-resistant Staphylococcus aureus.Intact mutS in laboratory-derived and clinical glycopeptide-intermediate Staphylococcus aureus strainsStructures of Staphylococcus aureus cell-wall complexes with vancomycin, eremomycin, and chloroeremomycin derivatives by 13C{19F} and 15N{19F} rotational-echo double resonanceIncreased glycan chain length distribution and decreased susceptibility to moenomycin in a vancomycin-resistant Staphylococcus aureus mutant.Moenomycin-resistance is associated with vancomycin-intermediate susceptibility in Staphylococcus aureus.Antimicrobial photodynamic activity of hypericin against methicillin-susceptible and resistant Staphylococcus aureus biofilms.Role of penicillin-binding protein 4 in expression of vancomycin resistance among clinical isolates of oxacillin-resistant Staphylococcus aureus.Transcriptional induction of the penicillin-binding protein 2 gene in Staphylococcus aureus by cell wall-active antibiotics oxacillin and vancomycin.Cell wall composition and decreased autolytic activity and lysostaphin susceptibility of glycopeptide-intermediate Staphylococcus aureus.Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus.Antimicrobial photodynamic therapy: study of bacterial recovery viability and potential development of resistance after treatment.The role of the Staphylococcal VraTSR regulatory system on vancomycin resistance and vanA operon expression in vancomycin-resistant Staphylococcus aureus.walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus.Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus.Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus.Lack of evidence for involvement of hypermutability in emergence of vancomycin-intermediate Staphylococcus aureus.Effect of gamma radiation and oregano essential oil on murein and ATP concentration of Staphylococcus aureus.Antimicrobial resistance in Staphylococcus aureus at the University of Chicago Hospitals: a 15-year longitudinal assessment in a large university-based hospital.Immuno-targeting of Staphylococcus aureus via surface remodeling complexes.Photodynamic inactivation of multi-resistant bacteria (PIB) - a new approach to treat superficial infections in the 21st centuryStructural basis of cell wall peptidoglycan amidation by the GatD/MurT complex of Staphylococcus aureus
P2860
Q24646677-0D86A139-5DDA-4A09-9C3A-039D05B2947CQ28217016-058ED309-89B5-4B0A-B9CE-09861F85ACDEQ28480400-26CF6F5F-5D4B-4BF3-86CC-9B520CB47585Q30401758-887408D3-778A-4D75-A505-29DA2EABC834Q30455758-7FC2F3A1-A437-4F3C-83D0-8EB5C5F96193Q33220466-0E09513F-6F9A-4E26-A9A7-0D1FBC7B03D6Q33264418-E50BD0DC-FC57-4E0E-B21F-F3C3012D914CQ33304273-EDCD146D-247B-4E1E-848A-62836E063310Q33722039-DAF82198-59CF-4A46-954F-780C6C9D68DBQ33974326-883AC8BE-9438-42EA-9FEF-F7F63D06C901Q34141289-57BCB5EF-AA60-4454-ACC9-9A4596DFC253Q34142416-26DF8EA2-392D-4FF1-993E-9A2BA6F1416FQ34198417-AEDC2B89-A799-40A0-B985-2D8AAC72E5BFQ34448260-6D73305F-71A6-4CA1-8F78-8DDAEDDFCF01Q34596835-33100EB9-3DA6-4E64-96E5-D201B1497C05Q34623924-7E19692F-984A-4946-AEA2-A6727D688F02Q34721614-EF5731A9-7332-4119-9904-53CA2B1B2309Q34747322-F4773B0D-FEF8-4783-98FD-443298EBCB32Q34823746-8C91A4C6-9E7E-4796-82A1-B31AA64F4FB8Q35023285-3B5A85E6-D73B-44D0-9498-C1BB4BC08A18Q35547555-F996494D-46E9-46CF-8C86-E204843FDC1DQ36824435-7D58BCE0-E376-4916-9D79-0BBEC9895AE2Q38293739-DBAC4214-9A32-4514-87F0-1B3AE944FC27Q38346543-F1D05F4F-10B9-4160-B1FB-858143E3A381Q39024865-D3790615-229F-4692-80FE-E1D367D75B3CQ39478780-6D220679-A338-4A16-BD53-55DC94B46DE7Q39731937-B32CAE93-7895-42FA-A690-5B9281E53011Q40166227-ED6C63D3-25EF-4178-8D52-F153F4823592Q40345457-8F1C385C-7070-4365-9F85-BAE4641F8B2FQ41823700-DC999DC0-DA42-4E81-9C8A-4E56919FFF78Q41874395-EF554856-E71D-4F0E-A26A-C37D47A5C77AQ42110968-EB4606CC-F958-4EFA-9267-7F2ED1160888Q42112516-9AB8804D-303C-4364-98E5-1504856ED1B4Q42119436-0440B872-CE28-4F8A-8D3B-AF641D4E45F5Q42859651-87D7248F-92C1-4DF7-A9AD-57397886E6A1Q43057225-064A3546-2D51-4047-9A7E-A4309D8534D7Q44492533-6472F6EE-94CF-4987-960A-F6388133850AQ48287021-0410BF99-9FA4-4952-9114-2E8A9494D290Q56019683-FB3CD760-8CA7-4EF1-B07B-E0FAFEDA4241Q58699706-07642019-5D2E-4C0F-BCDD-3C430E479CDE
P2860
A spectrum of changes occurs in peptidoglycan composition of glycopeptide-intermediate clinical Staphylococcus aureus isolates
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
A spectrum of changes occurs i ...... Staphylococcus aureus isolates
@ast
A spectrum of changes occurs i ...... Staphylococcus aureus isolates
@en
type
label
A spectrum of changes occurs i ...... Staphylococcus aureus isolates
@ast
A spectrum of changes occurs i ...... Staphylococcus aureus isolates
@en
prefLabel
A spectrum of changes occurs i ...... Staphylococcus aureus isolates
@ast
A spectrum of changes occurs i ...... Staphylococcus aureus isolates
@en
P2093
P2860
P1476
A spectrum of changes occurs i ...... Staphylococcus aureus isolates
@en
P2093
H Labischinski
S Boyle-Vavra
P2860
P304
P356
10.1128/AAC.45.1.280-287.2001
P407
P577
2001-01-01T00:00:00Z